OKYO Pharma Limited
OKYO
$1.57
-$0.11-6.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.27M | 1.27M | 1.86M | 1.86M | 561.70K |
| Gross Profit | -1.27M | -1.27M | -1.86M | -1.86M | -561.70K |
| SG&A Expenses | -- | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.25M | 1.25M | 1.88M | 1.88M | 1.67M |
| Operating Income | -1.25M | -1.25M | -1.88M | -1.88M | -1.67M |
| Income Before Tax | -1.29M | -1.29M | -1.94M | -1.94M | -2.05M |
| Income Tax Expenses | 0.00 | 0.00 | -923.00K | -923.00K | -708.90K |
| Earnings from Continuing Operations | -1.29M | -1.29M | -1.01M | -1.01M | -1.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.29M | -1.29M | -1.01M | -1.01M | -1.34M |
| EBIT | -1.25M | -1.25M | -1.88M | -1.88M | -1.67M |
| EBITDA | -1.25M | -1.25M | -1.88M | -1.88M | -1.67M |
| EPS Basic | -0.03 | -0.03 | -0.02 | -0.02 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -0.03 | -0.03 | -0.02 | -0.02 | -0.04 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 37.42M | 37.42M | 45.40M | 45.40M | 33.57M |
| Average Diluted Shares Outstanding | 37.42M | 37.42M | 45.40M | 45.40M | 33.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |